Top 3 most insightful comments as selected by Dr Allegretti:
(GI, Massachusetts)
(GI, Dr. Ari Grinspan, New York)
The client can proceed with a medical education strategy that targets a broad array of medical oncologists. Communication will focus on specific stages of the patient journey and the data that support the new test’s use in these stages. The pricing insight also helps forecast the size of the market opportunity.
The majority send more than 2 tests per month
GDH reflexed to EIA toxin testing is the most commonly available test followed by PCR
Openbiome is the most frequently used source for donor material
Most commonly cited reasons for not offering FMT is COVID related issues and lack of resources (for e.g. experience, personnel, facility)
What benefits do you believe micro-biome based therapeutics have above FMT?Physicians believe microbiome-based therapeutics are more effective and easier to use
Most commonly cited reasons are the need to learn more and limited efficacy